Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBOW Trial: RAY121 in Immunological Diseases
NCT06371417Phase 1Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Mar 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 1, open-label, single-arm trial of RAY121 in antiphospholipid syndrome (APS), Bullous Pemphigoid (BP), Behçet's disease (BD) and 3 more, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Adverse events. Started Aug 2024; status: recruiting.
02
Drugs
RAY121
03
Conditions
antiphospholipid syndrome (APS)Bullous Pemphigoid (BP)Behçet's disease (BD)dermatomyositis (DM)immune-mediated necrotizing myopathy (IMNM)
Beyond the preview
Go deeper on NCT06371417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06371417.